Matthew Lehman COO and designted CEO, Prima Biomed Ltd.

Australian biotechnology company Prima BioMed Ltd is one of the world’s leaders when it comes to cancer treatment. The focus on developing anti-cancer therapeutics based on the emerging technology of immunotherapy. Scientific research, product development and clinical trials are

the essentials of what they call the cutting edge of the fight against cancer. Prima BioMed’s technologies all result from research on the human immune system. In summary, the technology platforms behind the Product Pipeline are: Dendritic cell therapy, Monoclonal Antibodies.

CVac™ cell therapy is a new and groundbreaking technology for the treatment of cancer. It stimulates the production of immune cells, produced naturally in the body, that attack cancer cells.  Video: Frankfurt, 2012